Abstract:Hepatocellular carcinoma (HCC) is an aggressive malignancy, and its effective treatment has been hampered by drug resistance. Extracellular vesicle (EV) delivery of TNF-related apoptosis-inducing ligand (TRAIL) (EV-T) was demonstrated to be superior to recombinant TRAIL (rTRAIL) for cancer treatment previously. And AZD5582, a potent antagonist of inhibitors of apoptosis proteins (IAPs) can potentiate apoptosis-based cancer therapies. However, the combination of EV-T and AZD5582 has never been examined for their possible apoptosis inducing synergism in cancers. In this study, we proposed and tested the combination of EV-T and AZD5582 as a potential novel therapy for effective treatment of HCC. Two HCC lines Huh7 and HepG2 that are both resistant to rTRAIL were examined. The results confirmed that AZD5582 and EV-T are synergistic for apoptosis induction in some cancer lines including Huh7 and HepG2 while sparing normal cells. More importantly, this study revealed that TRAIL sensitization by AZD5582 is mediated through the concomitant suppression of anti-apoptotic factors including cFLIP, MCL-1, and IAPs (XIAP, Survivin and cIAP-1). Particularly the downregulation of cFLIP and IAP's appeared to be essential and necessary for the synergism between AZD5582 and TRAIL. In vivo, we first time demonstrated that the combined therapy with low doses of AZD5582 and EV-Ts triggered drastically enhanced apoptosis leading to the complete eradication of Huh7 tumor development without any apparent adverse side effects examined. We thus have unraveled the important molecular mechanism underlying TRAIL sensitization by AZD5582, rationalizing the next development of a combination therapy with AZD5582 and EV-T for HCC treatment.Key messagesIt confirmed the TRAIL sensitization by AZD5582, a potent antagonist of IAPs in hepatocarcinoma.It revealed that the sensitization is via the concomitant suppression of antiapoptotic factors including cFLIP, MCL-1, and IAPs.The downregulation of cFLIP and IAPs like Survivin appeared to be essential and necessary for the synergism between AZD5582 and nanosomal TRAIL.In vivo the combined therapy with AZD5582 and nanosomal TRAIL led to complete eradication of hepatocarcinoma tumors.This study has rationalized the next development of a combination therapy with AZD5582 and nanosomal TRAIL for cancer treatment.

Induction of apoptosis by HSP90 inhibitor 17-AAG and TRAIL in hepatocellular carcinoma cell lines

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy.

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

Combination of PHA-767491 with TRAIL Inhibits Proliferation of Hepatocellular Carcinoma Bel-7404 Cells

Inhibition of RIPK 1 expression and facilitation of TRAIL-induced hepatocellular carcinoma cell apoptosis by miR-141

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part Through the Inhibition of the Phosphatidylinositol 3-Kinase/akt Pathway

Inhibitory effect of 17AAG on proliferation and invasion of hepatocellular carcinoma cells

Hepatocytes Treated With Hbv X Protein As Cytotoxic Effectors Kill Primary Hepatocytes By Tnf-Alpha-Related Apoptosis-Induced Ligand-Mediated Mechanism

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma

Targeting Grp75 Improves Hsp90 Inhibitor Efficacy By Enhancing P53-Mediated Apoptosis In Hepatocellular Carcinoma

Targeting Heat Shock Factor-1 by Shrna Interference:A Potential Tool to Enhances Therapeutic Efficiency of 17-Aag on Colon Cancer in Vitro

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

[Lipopolysaccharide (LPS) Increases Tumor Necrosis Factor-Alpha Related Apoptosis Induced-Ligand (TRAIL) in Macrophages Killing HepG2 Cells].

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin